• gmp-verlag.de
  • GMP MANUAL Login
  • Shopping cart
Stay informed!

You’d like to be regularly informed on the latest developments in Good Manufacturing Practices?

 

Subscribe to our free GMP Newsletter LOGFILE!

>>> REGISTER NOW

The New USP <1231>
Water for Pharmaceutical Purposes

a detailed Overview

>>> ORDER NOW

Award for the
GMP Compliance Adviser

GMP knowledge that convinces.

Image

On 7 June 2016 Maas & Peither GMP Publishing has received a

SIPAward in the category
"Best New Success Story" and was awarded with the 3rd place.

The GMP MANUAL (now: GMP Compliance Adviser) impressed the jury with "Safe Drugs through Better GMP Understanding".


GMP Compliance Adviser

GMP in Practice: 24 chapters written by internationally renowned industry experts.

 

GMP Regulations: 8 chapters with the most important GMP guidelines and regulations.

 

Image

>>> READ MORE

TOP 5 GMP Downloads

1. Questionnaire for preparing GMP-inspections
More than 650 typical questions related to audits and inspections.


2. GDP Audit Checklist
More than 700 questions with reference to regulations.


3. GMP Fundamentals
A quick and comprehensive overview of the complex world of GMP.


4. Industry Guide to handle OOX Test Results
Every single step of the OOX process.


5. The New USP <1231>: Water for Pharmaceutical Purposes
A compact overview of the contents of the new version of USP <1231>.


>>> More Downloads

News about GMP/cGMP

2017-06-14

CFDA: 2016 Report on Drug Inspections

The China Food and Drug Administration (CFDA) released a detailed report on inspections conducted throughout the last year. A total of 431 inspections including pre-approval inspections, GMP certification inspections, GMP follow-up inspections, unannounced inspections, overseas inspections, GSP unannounced inspection and inspection observations are analysed therein.

 

As might have been expected two hotspots were identified as common findings: Missing data integrity and consistency of production processes. The problems listed range from missing retain samples, missing laboratory results, missing stability testings up to unsolved deviation problems.

Part V of the Annual Report deals with overseas inspections. Here are some numbers:

  • Originally, an overall of 49 inspections was planned to be conducted in 19 countries. 33 in Europe, six in Northern America, two in Southern America, six in Southeast Asia, one in India and one in Australia.
  • Finally, only seven of the 49 pharmaceutical manufacturers were inspected by the end of 2016.
  • 21 inspections were postponed, as the sites “could not accept an inspection” earlier than late 2017.
  • Eight foreign manufacturers proactively withdrew the import registration certificate during the organization of the inspection.
  • Three manufacturing sites were categorized to be insufficient.
  • An overall of three critical deviations and 18 major findings were detected. The problems mainly focused on Quality Control and Quality Assurance, Material System and Change Management and again on Data Integrity.
Click here to get to the Annual Report of the CFDA.

Source:
CFDA: What's new
Comments
No comment has yet been written about this news.
 
 
Literature recommendation
GMP Compliance Adviser
Single User Licence (yearly subscription)